Sequential seed backs AI to predict skin actives from multi‑omic non‑invasive tests
This article covers Sequential, a Cambridge biotech startup, which has raised £2.6m in a seed funding round to build an AI-powered discovery platform linking multi-omic, non-invasive clinical testing to the development of next-generation skin health ingredients. The funding aims to accelerate an AI discovery engine trained on Sequential’s clinical dataset to prioritise ingredient combinations for personal care and adjacent health categories, supporting product developers, investors and the UK personal care ecosystem.
Sequential, a Cambridge biotech startup, has raised £2.6m in a seed funding round to build an AI-powered discovery platform that links multi-omic, non-invasive clinical testing to the development of next‑generation skin health ingredients. The raise will back work on a discovery engine trained on Sequential’s clinical dataset, aiming to speed prediction and optimisation of active ingredient combinations for personal care and adjacent health categories.
Why it matters
The personal care market increasingly promises biomarker‑led benefits, but independent, clinical evidence remains scarce. Sequential’s approach — combining microbial and molecular analyses from non‑invasive samples — aims to create a dataset that can be used to test product impact on host and microbial biomarkers rather than relying solely on consumer perception or small trials.
That matters because greater rigour in ingredient discovery could change how companies substantiate claims, shorten the path from lab to validated product concepts, and shift investment toward data‑driven innovation in skin health. Sequential says the new funding is intended to accelerate construction of an AI model that can prioritise ingredient combinations for follow-up clinical validation.
Inside the product
Sequential runs a non‑invasive testing platform that integrates microbial and molecular data to map how ingredients and products alter biomarkers. The company reports one of the industry’s largest datasets: more than 50,000 samples, over 4,000 ingredients tested, and data from 10,000+ participants worldwide. That real‑world clinical dataset is the foundation for an AI discovery engine intended to predict which bioactive complexes are likely to produce meaningful biomarker changes.
Technically, Sequential combines systems biology, clinical research infrastructure and computational modelling to surface candidate actives that can then be validated in targeted clinical studies. The stated goal is to move beyond incremental formulation tweaks by using predictive models to systematically design and validate ingredient combinations.
Who are the investors?
The seed round was co‑led by Sparkfood and Corundum Systems Biology (CSB). Other participants include Dermazone Holdings, SOSV, Scrum Ventures, an ex‑General Partner at Index Ventures, and continued support from Innovate UK. The equity raise was £2.6m; Sequential says it has now secured a total of £5.6m in dilutive and non‑dilutive funding to date.
In the announcement, Anouk Veber, Ventures' Business Unit Leader in Sparkfood, commented:
Sequential has built a unique bridge between biology, clinical validation, and consumer product development, linking molecular and microbial biomarkers to real-world product performance. We believe their AI-driven platform will reshape how next-generation personal care products are developed and differentiated. This investment also aligns with Sparkfood's connected innovation strategy, opening the door to co-development opportunities and commercial synergies in the personal care space.
In the announcement, Hidehiko Otake, CEO of Corundum Systems Biology, stated:
Sequential's mission aligns with ours: to transform human health with the power of large datasets, the microbiome, and artificial intelligence. Our continued support in this round reflects our confidence in their vision and our shared commitment to redefining the future of personal care.
If you're researching potential backers in this space:
- Explore our list of biotech venture capital firms in the UK
- Browse our directory of biotech angel investors in the UK
Founder perspective
Sequential was founded by Dr Oliver Worsley, Petronille Houdart, and Dr Albert Dashi. The company frames its work as bringing “pharmaceutical‑grade evidence and computational precision” to personal care through large clinical datasets and AI.
In the announcement, Oliver Worsley, PhD, CEO and Co‑Founder of Sequential, said:
By applying artificial intelligence to one of the world's largest clinical datasets in dermatological health, we can both discover new skin biomarkers, and move beyond incremental formulation improvements and instead systematically design and validate breakthrough ingredient combinations. This investment allows us to scale that vision.
Worsley positions the funding as enabling scale‑up of the discovery pipeline — from data curation and model training to prioritisation of candidates for clinical validation — rather than immediate consumer product launches.
The bigger picture
The deal sits at the intersection of three trends: growing commercial interest in the microbiome and host‑microbe interactions, wider adoption of AI in R&D workflows, and a push for more rigorous evidence in consumer health claims. Support from Innovate UK in the funding mix underscores the role of public non‑dilutive funding in de‑risking early‑stage biotech work in the UK.
The announcement also reflects growing activity among biotech investors in consumer and dermatological health, as companies attempt to bridge lab science and marketable products. For Sequential, the test will be whether predictive models trained on observational and clinical datasets can reliably point to ingredients that survive rigorous validation and regulatory scrutiny.
This funding round highlights how UK biotech startups are increasingly combining clinical scale datasets, AI and systems biology to target consumer health markets — a trend likely to draw continued attention from both commercial investors and public funders across Europe.
They've invested in Sequential
Get to know these biotech investors
| Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|
 Dermazone Holdings | 2 investments investments | more info | |||
 SOSV | 8 investments investments | 10 contacts contacts | |||
 Scrum Ventures | 2 investments investments | more info | |||
 an ex-General Partner at Index Ventures | 2 investments investments | more info | |||
 Innovate UK Investor Partnership | 40 investments investments | more info |
Click here for a full list of 7,526+ startup investors in the UK